Newsroom of

Levo Therapeutics, Inc.

Levo Therapeutics is dedicated to advancing treatments for Prader-Willi syndrome and related disorders.

Levo Therapeutics Announces Publication of Phase 2 Study Results and Planned Phase 3 Study of Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome

​Levo Therapeutics Inc. announced today that JCI Insight has published the results of a Phase 2 study of intranasal carbetocin (LV-101) in patients with genetically confirmed Prader-Willi syndrome (PWS). Results from the study suggest that the investigational product LV-101 has marked effects on core features of PWS,…

Levo Therapeutics to License Exclusive Rights to Ferring Pharmaceuticals' Orphan-Designated Drug, Carbetocin, for the Treatment of Prader-Willi Syndrome

Levo Therapeutics, Inc. announced today that it has agreed to terms with Swiss-based Ferring Pharmaceuticals that, subject to contract, grant Levo Therapeutics worldwide rights to Ferring’s drug, carbetocin, for the treatment of Prader-Willi syndrome (PWS).  The agreement includes full data rights to the…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login